Evidence map›Paper›PMID 23980495›Full record

ReviewJournal of biomedical nanotechnology2013

Entering the era of nanoscience: time to be so small.

Vuk Uskoković

Abstract readReview
In one paragraph

Review in Journal of biomedical nanotechnology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Nanomedicine applications in women's health: state of the art.International journal of nanomedicine · 2018
    Review
  11. Ethical issues in nanomedicine: Tempest in a teapot?Medicine, health care, and philosophy · 2017
    Article
  12. Review
  13. Article
  14. Article
  15. When 1+1>2: Nanostructured composites for hard tissue engineering applications.Materials science & engineering. C, Materials for biological applications · 2015
    Review
  16. Article
  17. Article
  18. Review
  19. Amelogenin in Enamel Tissue Engineering.Advances in experimental medicine and biology · 2015
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Vuk UskokovićTherapeutic Micro and Nanotechnology Laboratory, Department of Bioengineering and Therapeutic Sciences, University of California, 1700 4th Street, San Francisco, CA 94158-2330, USA. vuk21@yahoo.com

Funding

Osteogenic Calcium Phosphate Nanoparticles with Designable Drug Release KineticsK99DE021416 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI USKOKOVIC, VUK · 2011 to 2012
$174k
NIDCR NIH HHS K99 DE021416NIDCR NIH HHS K99-DE021416
6 · The paper itself

Abstract

The field of nanoscience has produced more hype than probably any other branch of materials science and engineering in its history. Still, the potentials of this new field largely lay undiscovered ahead of us; what we have learnt so far with respect to the peculiarity of physical processes on the nanoscale is only the tip of an iceberg. Elaborated in this critical review is the idea that the surge of interest in physical chemistry of phenomena at the nanoscale presents a natural consequence of the spatial refinement of the human ability to controllably manipulate the substratum of our physical reality. Examples are given to illustrate the sensitivity of material properties to grain size on the nanoscale, a phenomenon that directly contributed to the rise of nanoscience as a special field of scientific inquiry. Main systemic challenges faced by the present and future scientists in this field are also mentioned. In part, this perspective article resembles standing on the constantly expanding seashore of the coast of nanoscience and nanoengineering and envisioning the parts of the island where the most significant advances may be expected to occur and where, therefore, most of the attention of scientist in this field is to be directed: (a) crossing the gap between life science and materials science; (b) increasing experimentation sensitivity; (c) crisscrossing theory and experiments; and (d) conjoining top-down and bottom-up synthetic approaches. As for materials and the application areas discussed, a special emphasis is placed on calcium phosphate nanoparticles and their usage in controlled drug delivery devices and other applications of biomedical relevance. It is argued that the properties of nanoparticles as drug carriers often comprise the critical determinant for- the efficacy of the drug therapy. Therefore, the basic properties of nanoparticles to be optimized for the purpose of maximizing this efficacy are discussed: size, size distribution, morphology, polymorphic nature, crystallinity, biocompatibility, biodegradability, drug elution profiles, and aggregation propensity.

Indexed as

Biocompatible MaterialsDelayed-Action PreparationsHumansNanocapsulesNanomedicineScienceBiocompatible MaterialsDelayed-Action PreparationsNanocapsules

Identifiers

PMID23980495
PMCPMC3768021

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.